On May 23, the Drug Administration of Vietnam, the Ministry of Health, issued an emergency license to add molnupiravir with a dose of 200 mg produced by Stellapharm Vietnam Company.
The Drug Administration of Vietnam continues to make three conditions attached to the urgent licensing decision that enterprises must have satisfactory quality of raw materials before production; continue to monitor and check drug quality every month after being granted circulation registration certificates; continue to study the drug’s stability and submit research data, updated records of expiry date for appraisal as required by the ASEAN Common Technical Dossier.
According to a representative of Stellapharm Company, in the context that the Covid-19 epidemic is under control in the country, the need to use molnupiravir is not as urgent as before. However, the decision to license the drug this time helps the company to have more products to serve domestic and export needs.
Thus, up to now, Vietnam has 4 types drug molnupiravir emergency authorization. In which, there are 3 types licensed on February 17, including Molravir 400 of Boston Pharmaceutical Joint Stock Company in Vietnam, Movinavir 200 mg of Mekorpha Pharmaceutical – Chemical Joint Stock Company and Molnupiravir Stella 400 of Co., Ltd. Stellapharm.
Molnupiravir is an active ingredient with antiviral activity. In the first quarter, when Covid-19 broke out strongly in the country, the drug was considered an important “weapon” in treating F0 at home, helping to reduce the viral load when used in the early stages of the disease, thereby reducing the risk of infection. worsening and death.
Molnupiravir is sold at drugstores nationwide from February. Buyers must have a prescription certified by a doctor or hospital. Children, pregnant women should not take this medicine; Do not use post- or pre-exposure prophylaxis to prevent Covid-19.
People in Hanoi buy the drug molnupiravir. Image: Loc Chung
Chile
at Blogtuan.info – Source: vnexpress.net – Read the original article here
